<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286882</url>
  </required_header>
  <id_info>
    <org_study_id>B7881001</org_study_id>
    <secondary_id>FIH</secondary_id>
    <secondary_id>2014-004022-18</secondary_id>
    <nct_id>NCT02286882</nct_id>
  </id_info>
  <brief_title>A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-06409577 is a new compound proposed for the treatment of diabetic nephropathy. The primary
      purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single
      oral doses of PF-06409577 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was terminated prematurely on June 19, 2015 for business reasons. There were no
    safety concerns in the study which led to the decision.
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Test Values of Potential Clinical Importance</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Findings (Including Bood Pressure and Pulse Rate) of Potential Clinical Importance</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Echocardiogram Findings of Potential Clinical Importance</measure>
    <time_frame>0-48 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Time 24 hours (AUC24) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours post dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to time 24 hours post dose (AUC24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - infinity)] for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>AUC (0 - infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - infinity). It is obtained from AUC (0 - t) plus AUC (t - infinity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Plasma Decay Half-Life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for PF-06409577</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of PF-06409577 excreted in the urine over 24 hours (Ae24)</measure>
    <time_frame>0-24 hours post dose</time_frame>
    <description>Total amount of unchanged drug excreted in the urine over 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of PF-06409577 excreted in the urine over 24 hours, expressed as percent of dose (%Ae24)</measure>
    <time_frame>0-24 hours post dose</time_frame>
    <description>Total amount of unchanged drug excreted in the urine over 24 hours, expressed as percent of dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance for PF-06409577</measure>
    <time_frame>0-24 hours post dose</time_frame>
    <description>Renal clearance of a drug is a measure of the rate at which a drug is excreted unchanged into urine.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9: PF-06409577 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06409577 or Placebo</intervention_name>
    <description>PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort</description>
    <arm_group_label>Cohort 1: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 2: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 3: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 4: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 5: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 6: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 7: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 8: PF-06409577 or placebo</arm_group_label>
    <arm_group_label>Cohort 9: PF-06409577 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, or female subjects of non childbearing potential.

          -  Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight &gt;50 kg

        Exclusion Criteria:

        - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
        gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
        (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at
        time of dosing)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single Ascending Dose</keyword>
  <keyword>healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

